Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Travere Therapeutics Inc TVTX

Healthcare Biotechnology
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for... see more

Recent & Breaking News (NDAQ:TVTX)

Retrophin Enters into U.S. License Agreement for Thiola® (Tiopronin)

Business Wire May 29, 2014

Retrophin Names Alvin Shih, M.D. Executive Vice President of Research and Development

Business Wire May 29, 2014

Retrophin Names Stephen Aselage President and Chief Operations Officer

Business Wire May 28, 2014

Retrophin Reports First Quarter 2014 Financial Results

Business Wire May 14, 2014

Retrophin to Report First Quarter 2014 Financial Results

Business Wire May 12, 2014

Retrophin Initiates Global Access for RE-024 in Pantothenate Kinase-Associated Neurodegeneration (PKAN)

Business Wire May 12, 2014

Retrophin Updates Financial Guidance for 2014 and 2015 and Provides Corporate Update

Business Wire April 14, 2014

Retrophin Reports Full-Year 2013 Financial Results

Business Wire March 27, 2014

The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014

GlobeNewswire March 27, 2014

Retrophin Completes Acquisition of Manchester Pharmaceuticals

Business Wire March 27, 2014

Retrophin Announces Agreement to Acquire Manchester Pharmaceuticals

Business Wire February 12, 2014

Retrophin to Present at the 16th Annual BIO CEO & Investor Conference

Business Wire February 4, 2014

Retrophin Announces Pricing of Public Offering of Common Shares

Business Wire January 10, 2014

Retrophin Announces Public Offering of Common Stock

Business Wire January 7, 2014

Retrophin Unveils New Clinical Development Candidate RE-034, An ACTH Analog

Business Wire December 17, 2013

Retrophin Withdraws Offer for Transcept Pharmaceuticals

Business Wire December 16, 2013

Retrophin Announces Agreement to Acquire Kyalin Biosciences

Business Wire December 12, 2013

Retrophin to Co-Sponsor Clinical Trial of Intranasal Oxytocin for Schizophrenia

Business Wire December 12, 2013

Retrophin Signs U.S. License Agreement for Syntocinon(TM) Nasal Spray (Oxytocin)

Business Wire December 12, 2013

Retrophin, Inc. Reports Third Quarter 2013 Operational and Financial Results

Business Wire November 18, 2013